Xiumei Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiumei Hu has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- Lei Zheng
Department of Laboratory Medicine Nanfang Hospital Southern Medical University Guangzhou China
8 shared publications - Qian Wang
Southern Medical University
8 shared publications Mei Huang
Center for Clinical Laboratory Zhujiang Hospital Southern Medical University Guangzhou P. R. China
6 shared publicationsRuyi Zhang
Department of Laboratory Medicine, Guangdong Provincial Key Laboratory of Precision Medical Diagnostics, Guangdong Engineering and Technology Research Center for Rapid Diagnostic Biosensors, Guangdong Provincial Key Laboratory of Single‐cell and Extracellular Vesicles, Nanfang Hospital Southern Medical University Guangzhou P. R. China
5 shared publicationsYiyi Huang
Department of Laboratory Medicine, Guangdong Provincial Key Laboratory of Precision Medical Diagnostics, Guangdong Engineering and Technology Research Center for Rapid Diagnostic Biosensors, Guangdong Provincial Key Laboratory of Single‐cell and Extracellular Vesicles, Nanfang Hospital Southern Medical University Guangzhou P. R. China
5 shared publicationsFan Bu
Zhejiang University
4 shared publications
Latest Publications
- Open Access
- 10 June 2026
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Successful treatment of an NDM-5-producing, carbapenem-resistant Salmonella Kentucky ST198 infection with aztreonam and ceftazidime-avibactam in a patient with acute erythroid leukemia: a case report
Introduction: Salmonella enterica serotype Kentucky ( S . Kentucky) is a globally distributed food-borne zoonotic pathogen. It is increasingly associated with multi-drug resistance (MDR), notably to ciprofloxacin, a trend largely attributed to antibiotic overuse in humans and livestock. Case presentation: An acute erythroid leukemia (AML-M6) man was found to be infected with carbapenem-resistant (CR) Salmonella enterica after chemotherapy. Salmonella serum agglutination test showed that the strain belonged to S . Kentucky. Antimicrobial susceptibility test showed that this strain is an MDR strain (resistant to carbapenems, ciprofloxacin, third-generation cephalosporins). Carbapenemase production was assessed via a colloidal gold immunochromatography assay and indicated expression of an NDM enzyme. Whole genome sequencing (WGS) revealed that this strain carried blaNDM-5, blaCTXM-55, and blaTEM-1 genes. Based on the identification of an NDM carbapenemase, in vitro synergy testing was performed, which demonstrated a synergistic effect between aztreonam and ceftazidime-avibactam. The patient was successfully treated with this combination regimen and recovered. Conclusions: This report describes an unusual infection caused by an NDM-5-producing S . Kentucky in an immunocompromised host. It underscores the necessity of employing combined phenotypic, immunologic, and molecular diagnostics to rapidly elucidate resistance mechanisms in such complex cases. Guided by this comprehensive analysis, the combination of aztreonam and ceftazidime-avibactam proved to be an effective, mechanism-based therapeutic strategy, highlighting its value in managing challenging infections in patients with hematological malignancies. Clinical trial number: Not applicable.
- 10 June 2026
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Open AccessSuccessful treatment of an NDM-5-producing, carbapenem-resistant Salmonella Kentucky ST198 infection with aztreonam and ceftazidime-avibactam in a patient with acute erythroid leukemia: a case report
Introduction: Salmonella enterica serotype Kentucky ( S . Kentucky) is a globally distributed food-borne zoonotic pathogen. It is increasingly associated with multi-drug resistance (MDR), notably to ciprofloxacin, a trend largely attributed to antibiotic overuse in humans and livestock. Case presentation: An acute erythroid leukemia (AML-M6) man was found to be infected with carbapenem-resistant (CR) Salmonella enterica after chemotherapy. Salmonella serum agglutination test showed that the strain belonged to S . Kentucky. Antimicrobial susceptibility test showed that this strain is an MDR strain (resistant to carbapenems, ciprofloxacin, third-generation cephalosporins). Carbapenemase production was assessed via a colloidal gold immunochromatography assay and indicated expression of an NDM enzyme. Whole genome sequencing (WGS) revealed that this strain carried blaNDM-5, blaCTXM-55, and blaTEM-1 genes. Based on the identification of an NDM carbapenemase, in vitro synergy testing was performed, which demonstrated a synergistic effect between aztreonam and ceftazidime-avibactam. The patient was successfully treated with this combination regimen and recovered. Conclusions: This report describes an unusual infection caused by an NDM-5-producing S . Kentucky in an immunocompromised host. It underscores the necessity of employing combined phenotypic, immunologic, and molecular diagnostics to rapidly elucidate resistance mechanisms in such complex cases. Guided by this comprehensive analysis, the combination of aztreonam and ceftazidime-avibactam proved to be an effective, mechanism-based therapeutic strategy, highlighting its value in managing challenging infections in patients with hematological malignancies. Clinical trial number: Not applicable.
- Open Access
- 29 December 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Deep learning-driven morphological fingerprinting: rapid, accurate and low-cost pathogen identification via the analysis of dried patterns of droplets
Bloodstream infections (BSIs) are life-threatening conditions with rising mortality, urgently requiring rapid pathogen identification to guide timely antib
- 29 December 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Open AccessDeep learning-driven morphological fingerprinting: rapid, accurate and low-cost pathogen identification via the analysis of dried patterns of droplets
Bloodstream infections (BSIs) are life-threatening conditions with rising mortality, urgently requiring rapid pathogen identification to guide timely antib
- Open Access
- 19 August 2025
- Published by Elsevier in LabMed Discovery
- Vol. 2 (3)
Biological properties and clinical applications of ceftobiprole: Current status and perspective review
- 19 August 2025
- Published by Elsevier in LabMed Discovery
- Vol. 2 (3)
Open AccessBiological properties and clinical applications of ceftobiprole: Current status and perspective review
- Open Access
- 18 August 2025
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 14 (8) , e70152
Extracellular Vesicles Containing MDP Derived from Lactobacillus rhamnosus GG Inhibit HSV‐2 Infection by Activating the NOD2‐IFN‐I Signalling Pathway
The immune evasion strategies and lifelong latency of herpes simplex virus type 2 (HSV‐2) present significant challenges for effective treatment. Recent studies have demonstrated that the commensal microbiota plays an important role in regulating immunity against viral infections. We previously reported that Lactobacillus rhamnosus GG (LGG) activates the expression of type I interferons (IFN‐I) to inhibit HSV‐2 infection. However, the specific molecular mechanisms remain unclear. Bacterial extracellular vesicles (EVs) are small lipid bilayer‐bound particles secreted by bacteria, which can serve as intercellular communication vehicles between the host and pathogens, functioning as immunomodulatory vectors defending against viral infections. In this study, we confirmed that LGG‐EVs activate the nucleotide‐binding oligomerisation domain‐containing protein 2 (NOD2)‐IFN‐I signalling pathway, inducing the expression of interferon‐stimulated genes (ISGs) to combat HSV‐2 infection both in vivo and in vitro. Furthermore, we explored the specific components within LGG‐EVs and identified the presence of muramyl dipeptide (MDP). We demonstrated that MDP‐enriched LGG‐EVs effectively inhibit HSV‐2 infection via activation of the NOD2‐IFN‐I pathway. These findings suggest that LGG‐EVs could serve as a novel therapeutic strategy for HSV‐2 and provide a mechanistic foundation for future antiviral research.
- 18 August 2025
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 14 (8) , e70152
Open AccessExtracellular Vesicles Containing MDP Derived from Lactobacillus rhamnosus GG Inhibit HSV‐2 Infection by Activating the NOD2‐IFN‐I Signalling Pathway
The immune evasion strategies and lifelong latency of herpes simplex virus type 2 (HSV‐2) present significant challenges for effective treatment. Recent studies have demonstrated that the commensal microbiota plays an important role in regulating immunity against viral infections. We previously reported that Lactobacillus rhamnosus GG (LGG) activates the expression of type I interferons (IFN‐I) to inhibit HSV‐2 infection. However, the specific molecular mechanisms remain unclear. Bacterial extracellular vesicles (EVs) are small lipid bilayer‐bound particles secreted by bacteria, which can serve as intercellular communication vehicles between the host and pathogens, functioning as immunomodulatory vectors defending against viral infections. In this study, we confirmed that LGG‐EVs activate the nucleotide‐binding oligomerisation domain‐containing protein 2 (NOD2)‐IFN‐I signalling pathway, inducing the expression of interferon‐stimulated genes (ISGs) to combat HSV‐2 infection both in vivo and in vitro. Furthermore, we explored the specific components within LGG‐EVs and identified the presence of muramyl dipeptide (MDP). We demonstrated that MDP‐enriched LGG‐EVs effectively inhibit HSV‐2 infection via activation of the NOD2‐IFN‐I pathway. These findings suggest that LGG‐EVs could serve as a novel therapeutic strategy for HSV‐2 and provide a mechanistic foundation for future antiviral research.
- Top Cited PapersOpen Access
- 22 January 2025
- Published by Taylor & Francis in Gut Microbes
- Vol. 17 (1) , 2452229
Bacterial extracellular vesicles in the initiation, progression and treatment of atherosclerosis
Atherosclerosis is the primary cause of cardiovascular and cerebrovascular diseases. However, current anti-atherosclerosis drugs have shown conflicting therapeutic outcomes, thereby spurring the search for novel and effective treatments. Recent research indicates the crucial involvement of oral and gastrointestinal microbiota in atherosclerosis. While gut microbiota metabolites, such as choline derivatives, have been extensively studied and reviewed, emerging evidence suggests that bacterial extracellular vesicles (BEVs), which are membrane-derived lipid bilayers secreted by bacteria, also play a significant role in this process. However, the role of BEVs in host-microbiota interactions remains insufficiently explored. This review aims to elucidate the complex communication mediated by BEVs along the gut-heart axis. In this review, we summarize current knowledge on BEVs, with a specific focus on how pathogen-derived BEVs contribute to the promotion of atherosclerosis, as well as how BEVs from gut symbionts and probiotics may mitigate its progression. We also explore the potential and challenges associated with engineered BEVs in the prevention and treatment of atherosclerosis. Finally, we discuss the benefits and challenges of using BEVs in atherosclerosis diagnosis and treatment, and propose future research directions to address these issues.
- 22 January 2025
- Published by Taylor & Francis in Gut Microbes
- Vol. 17 (1) , 2452229
Top Cited PapersOpen AccessBacterial extracellular vesicles in the initiation, progression and treatment of atherosclerosis
Atherosclerosis is the primary cause of cardiovascular and cerebrovascular diseases. However, current anti-atherosclerosis drugs have shown conflicting therapeutic outcomes, thereby spurring the search for novel and effective treatments. Recent research indicates the crucial involvement of oral and gastrointestinal microbiota in atherosclerosis. While gut microbiota metabolites, such as choline derivatives, have been extensively studied and reviewed, emerging evidence suggests that bacterial extracellular vesicles (BEVs), which are membrane-derived lipid bilayers secreted by bacteria, also play a significant role in this process. However, the role of BEVs in host-microbiota interactions remains insufficiently explored. This review aims to elucidate the complex communication mediated by BEVs along the gut-heart axis. In this review, we summarize current knowledge on BEVs, with a specific focus on how pathogen-derived BEVs contribute to the promotion of atherosclerosis, as well as how BEVs from gut symbionts and probiotics may mitigate its progression. We also explore the potential and challenges associated with engineered BEVs in the prevention and treatment of atherosclerosis. Finally, we discuss the benefits and challenges of using BEVs in atherosclerosis diagnosis and treatment, and propose future research directions to address these issues.
- 14 January 2025
- Published by Elsevier in Life Sciences
- Vol. 363, 123393
UGP2, a novel target gene of TP53, inhibits endothelial cells apoptosis and atherosclerosis
- 14 January 2025
- Published by Elsevier in Life Sciences
- Vol. 363, 123393
UGP2, a novel target gene of TP53, inhibits endothelial cells apoptosis and atherosclerosis
- 1 September 2024
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 44 (9) , 2088-2107
HCC-1 Accelerates Atherosclerosis by Inducing Endothelial Cell and Macrophage Pyroptosis and Serves as an Early Diagnostic Biomarker
BACKGROUND: HCC-1 (hemofiltrate CC chemokine-1), a CC-type chemokine, exerts function to change intracellular calcium concentration, induce leukocyte, and manipulate enzyme release especially in monocytes. It has been reported that HCC-1 can predict the persistent acute kidney injury or suppress hepatocellular carcinoma by modulating cell cycle and promoting apoptosis; however, the effect of HCC-1 on atherosclerosis is poorly understood. Here, we aimed to clarify the function and mechanism of HCC-1 in atherosclerosis and whether it could serve as a novel biomarker for the diagnosis of atherosclerosis. METHODS: HCC-1 expression in serum, atherosclerotic plaques, and normal arterial tissue from patients with atherosclerosis and control group was assessed by ELISA, immunohistochemistry and confocal microscope, and bioinformatic analysis. The atherosclerotic model of HCC-1 overexpressing and control mice was generated by tail vein injection of adeno-associated virus serotype 9–HCC-1 on an ApoE −/− background. Cell adhesion, polarization, and pyroptosis were evaluated in vitro. The relationship between HCC-1 concentration in serum and atherosclerosis was analyzed in patients with atherosclerosis. RESULTS: HCC-1 expression was positively correlated with the occurrence and stable-unstable switch of atherosclerosis under bioinformatic analysis, which is further supported by the results of increased HCC-1 expression in atherosclerosis patients both in serum and atherosclerotic plaque. adeno-associated virus serotype 9–HCC-1 mice had higher levels of inflammatory factors, increased macrophage accumulation and pyroptotic rate in plaque, and decreased atherosclerotic plaque stability. In vitro, HCC-1 promoted monocyte adhesion and M1 polarization and induced inflammation and pyroptosis both in endothelial cells and macrophages. CONCLUSIONS: HCC-1 expression was increased in patients with atherosclerosis, and HCC-1 overexpression accelerated atherosclerotic burden via an enhancement in monocyte recruitment, M1 polarization, and pyroptosis both in endothelial cells and macrophages. Our findings suggested that HCC-1 may serve as an early biomarker for the diagnosis of atherosclerosis, with the capacity to reflect the degree of stenosis.
- 1 September 2024
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 44 (9) , 2088-2107
HCC-1 Accelerates Atherosclerosis by Inducing Endothelial Cell and Macrophage Pyroptosis and Serves as an Early Diagnostic Biomarker
BACKGROUND: HCC-1 (hemofiltrate CC chemokine-1), a CC-type chemokine, exerts function to change intracellular calcium concentration, induce leukocyte, and manipulate enzyme release especially in monocytes. It has been reported that HCC-1 can predict the persistent acute kidney injury or suppress hepatocellular carcinoma by modulating cell cycle and promoting apoptosis; however, the effect of HCC-1 on atherosclerosis is poorly understood. Here, we aimed to clarify the function and mechanism of HCC-1 in atherosclerosis and whether it could serve as a novel biomarker for the diagnosis of atherosclerosis. METHODS: HCC-1 expression in serum, atherosclerotic plaques, and normal arterial tissue from patients with atherosclerosis and control group was assessed by ELISA, immunohistochemistry and confocal microscope, and bioinformatic analysis. The atherosclerotic model of HCC-1 overexpressing and control mice was generated by tail vein injection of adeno-associated virus serotype 9–HCC-1 on an ApoE −/− background. Cell adhesion, polarization, and pyroptosis were evaluated in vitro. The relationship between HCC-1 concentration in serum and atherosclerosis was analyzed in patients with atherosclerosis. RESULTS: HCC-1 expression was positively correlated with the occurrence and stable-unstable switch of atherosclerosis under bioinformatic analysis, which is further supported by the results of increased HCC-1 expression in atherosclerosis patients both in serum and atherosclerotic plaque. adeno-associated virus serotype 9–HCC-1 mice had higher levels of inflammatory factors, increased macrophage accumulation and pyroptotic rate in plaque, and decreased atherosclerotic plaque stability. In vitro, HCC-1 promoted monocyte adhesion and M1 polarization and induced inflammation and pyroptosis both in endothelial cells and macrophages. CONCLUSIONS: HCC-1 expression was increased in patients with atherosclerosis, and HCC-1 overexpression accelerated atherosclerotic burden via an enhancement in monocyte recruitment, M1 polarization, and pyroptosis both in endothelial cells and macrophages. Our findings suggested that HCC-1 may serve as an early biomarker for the diagnosis of atherosclerosis, with the capacity to reflect the degree of stenosis.
- Open Access
- 18 January 2024
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 38 (1-2) , e25008
Blood culture quality and turnaround time of clinical microbiology laboratories in Chinese Teaching Hospitals: A multicenter study
Purpose: Blood culture (BC) remains the gold standard for the diagnosis of bloodstream infections. Improving the quality of clinical BC samples, optimizing BC performance, and accelerating antimicrobial susceptibility test (AST) results are essential for the early detection of bloodstream infections and specific treatments.Methods: We conducted a retrospective multicenter study using 450,845 BC specimens from clinical laboratories obtained from 19 teaching hospitals between 1 January 2021 and 31 December 2021. We evaluated key performance indicators (KPIs), turnaround times (TATs), and frequency distributions of processing in BC specimens. We also evaluated the AST results of clinically significant isolates for four different laboratory workflow styles.Results: Across the 10 common bacterial isolates (n = 16,865) and yeast isolates (n = 1011), the overall median (interquartile range) TATs of AST results were 2.67 (2.05–3.31) and 3.73 (2.98–4.64) days, respectively. The specimen collections mainly occurred between 06:00 and 24:00, and specimen reception and loadings mainly between 08:00 and 24:00. Based on the laboratory workflows of the BCs, 16 of the 19 hospitals were divided into four groups. Time to results (TTRs) from specimen collection to the AST reports were 2.35 (1.95–3.06), 2.61 (1.98–3.32), 2.99 (2.60–3.87), and 3.25 (2.80–3.98) days for groups I, II, III, and IV, respectively.Conclusion: This study shows the related BC KPIs and workflows in different Chinese hospitals, suggesting that laboratory workflow optimization can play important roles in shortening time to AST reports and initiation of appropriate timely treatment.
- 18 January 2024
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 38 (1-2) , e25008
Open AccessBlood culture quality and turnaround time of clinical microbiology laboratories in Chinese Teaching Hospitals: A multicenter study
Purpose: Blood culture (BC) remains the gold standard for the diagnosis of bloodstream infections. Improving the quality of clinical BC samples, optimizing BC performance, and accelerating antimicrobial susceptibility test (AST) results are essential for the early detection of bloodstream infections and specific treatments.Methods: We conducted a retrospective multicenter study using 450,845 BC specimens from clinical laboratories obtained from 19 teaching hospitals between 1 January 2021 and 31 December 2021. We evaluated key performance indicators (KPIs), turnaround times (TATs), and frequency distributions of processing in BC specimens. We also evaluated the AST results of clinically significant isolates for four different laboratory workflow styles.Results: Across the 10 common bacterial isolates (n = 16,865) and yeast isolates (n = 1011), the overall median (interquartile range) TATs of AST results were 2.67 (2.05–3.31) and 3.73 (2.98–4.64) days, respectively. The specimen collections mainly occurred between 06:00 and 24:00, and specimen reception and loadings mainly between 08:00 and 24:00. Based on the laboratory workflows of the BCs, 16 of the 19 hospitals were divided into four groups. Time to results (TTRs) from specimen collection to the AST reports were 2.35 (1.95–3.06), 2.61 (1.98–3.32), 2.99 (2.60–3.87), and 3.25 (2.80–3.98) days for groups I, II, III, and IV, respectively.Conclusion: This study shows the related BC KPIs and workflows in different Chinese hospitals, suggesting that laboratory workflow optimization can play important roles in shortening time to AST reports and initiation of appropriate timely treatment.
- Open Access
- 25 August 2023
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
- Vol. 16 (6) , 1966-1978
Lactobacillus rhamnosus GG Regulates Host IFN-I Through the RIG-I Signalling Pathway to Inhibit Herpes Simplex Virus Type 2 Infection
Numerous recent studies have demonstrated that the commensal microbiota plays an important role in host immunity against infections. During the infection process, viruses can exhibit substantial and close interactions with the commensal microbiota. However, the associated mechanism remains largely unknown. Therefore, in this study, we explored the specific mechanisms by which the commensal microbiota modulates host immunity against viral infections. We found that the expression levels of type I interferon (IFN-I) and antiviral priming were significantly downregulated following the depletion of the commensal microbiota due to treatment with broad-spectrum antibiotics (ABX). In addition, we confirmed a unique molecular mechanism underlying the induction of IFN-I mediated by the commensal microbiota. In vivo and in vitro experiments confirmed that Lactobacillus rhamnosus GG (LGG) can suppress herpes simplex virus type 2 (HSV-2) infection by inducing IFN-I expression via the retinoic acid-inducible gene-I (RIG-I) signalling pathway. Therefore, the commensal microbiota-induced production of IFN-I provides a potential therapeutic approach to combat viral infections. Altogether, understanding the complexity and the molecular aspects linking the commensal microbiota to health will help provide the basis for novel therapies already being developed. Graphical Abstract
- 25 August 2023
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
- Vol. 16 (6) , 1966-1978
Open AccessLactobacillus rhamnosus GG Regulates Host IFN-I Through the RIG-I Signalling Pathway to Inhibit Herpes Simplex Virus Type 2 Infection
Numerous recent studies have demonstrated that the commensal microbiota plays an important role in host immunity against infections. During the infection process, viruses can exhibit substantial and close interactions with the commensal microbiota. However, the associated mechanism remains largely unknown. Therefore, in this study, we explored the specific mechanisms by which the commensal microbiota modulates host immunity against viral infections. We found that the expression levels of type I interferon (IFN-I) and antiviral priming were significantly downregulated following the depletion of the commensal microbiota due to treatment with broad-spectrum antibiotics (ABX). In addition, we confirmed a unique molecular mechanism underlying the induction of IFN-I mediated by the commensal microbiota. In vivo and in vitro experiments confirmed that Lactobacillus rhamnosus GG (LGG) can suppress herpes simplex virus type 2 (HSV-2) infection by inducing IFN-I expression via the retinoic acid-inducible gene-I (RIG-I) signalling pathway. Therefore, the commensal microbiota-induced production of IFN-I provides a potential therapeutic approach to combat viral infections. Altogether, understanding the complexity and the molecular aspects linking the commensal microbiota to health will help provide the basis for novel therapies already being developed. Graphical Abstract
- Open Access
- 7 July 2023
- Published by Elsevier in Atherosclerosis
- Vol. 379, 117183
LncRNA RP4-639F20.1 interacts with THRAP3 to attenuate atherosclerosis by regulating c-FOS in vascular smooth muscle cells proliferation and migration
- 7 July 2023
- Published by Elsevier in Atherosclerosis
- Vol. 379, 117183
Open AccessLncRNA RP4-639F20.1 interacts with THRAP3 to attenuate atherosclerosis by regulating c-FOS in vascular smooth muscle cells proliferation and migration